U.S. Senate Hearing: Oversight of the FDA's Foreign Drug Manufacturing Inspection Process (28/35)

< Prev Next >
Deputy Director for Regulatory Programs, Center for Drug Evaluation and Research Food and Drug Administration, Douglas Throckmorton M.D. speaks by video conference during a United States Senate Finance Committee hearing on "COVID-19 and Beyond: Oversight of the FDA's Foreign Drug Manufacturing Inspection Process" at the US Capitol in Washington, DC on June 2, 2020.<br />
Credit: Andrew Caballero-Reynolds / Pool via CNP/AdMedia
Deputy Director for Regulatory Programs, Center for Drug Evaluation and Research Food and Drug Administration, Douglas Throckmorton M.D. speaks by video conference during a United States Senate Finance Committee hearing on "COVID-19 and Beyond: Oversight of the FDA's Foreign Drug Manufacturing Inspection Process" at the US Capitol in Washington, DC on June 2, 2020.
Credit: Andrew Caballero-Reynolds / Pool via CNP/AdMedia

Filename: adm_060220_Finance-Drugs_CNP_013.jpg
Copyright
Date: 2 Jun 2020
Restrictions:
2003 - 2016 AdMedia Photo